Article

Personalized prophylactic antiemetic regimens for the control of chemotherapy-induced nausea and vomiting by pharmacogenetic analysis of three receptors genes:<i>HTR3A, HTR3B, TACR1</i>

2024-12-30

Abstract excerpt

<h4>Background</h4> Contemporary prophylactic antiemetic regimens have improved the control of chemotherapy-induced nausea and vomiting (CINV). However, many patents still have suboptimal control with over 50% still suffering from nausea. We postulate that an individual’s pharmacogenetic profile may aid in optimizing the use of antiemetic prophylaxis. This study aimed to correlate the genetic determinants of indiv...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d61dd0e7-3c8e-5e48-93b6-e40e3ff13ad1
DOI: 10.1101/2024.12.29.24319754

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Personalized prophylactic antiemetic regimens for the control of chemotherapy-induced nausea and vomiting by pharmacogenetic analysis of three receptors genes:<i>HTR3A, HTR3B, TACR1</i>DOI 10.1101/2024.12.29.24319754Read

Polymorphism in HTR3D shows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy.Semantic proximity Read

Pharmacogenetics of Chemotherapy-Induced Nausea and VomitingSemantic proximity Read

Single Nucleotide Polymorphism Directed Antiemetic Treatment in Women With Breast Cancer Treated With Neo- or Adjuvant Chemotherapy: A Randomised Multicentre Phase II Study. (EudraCT: 2015-000658-39).Semantic proximity Read

Gene polymorphisms of TACR1 serve as the potential pharmacogenetic predictors of response to the neurokinin-1 receptor antagonist-based antiemetic regimens: a candidate-gene association study in breast cancer patients.Semantic proximity Read

Genetic Risk Factors Associated With Antiemetic Efficacy of Palonosetron, Aprepitant, and Dexamethasone in Japanese Breast Cancer Patients Treated With Anthracycline-based Chemotherapy.Semantic proximity Read

A review of the literature on the relationships between genetic polymorphisms and chemotherapy-induced nausea and vomiting.Semantic proximity Read

Polymorphisms of 5-hydroxytryptamine receptor type 3B gene and clinical characteristics for vomiting after breast surgery in chinese han female population.Semantic proximity Read

Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors.Semantic proximity Read

Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy.Semantic proximity Read

Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.Semantic proximity Read

Pharmacogenetics as a Future Tool to Risk-Stratify Breast Cancer Patients According to Chemotoxicity Potential from the Doxorubicin Hydrochloride and Cyclophosphamide (AC) RegimenSemantic proximity Read

Clinical and genetic factors associated with nausea and vomiting in cancer patients receiving opioids.Semantic proximity Read